UPCC 13118: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant Palbociclib and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
Enrolling By Invitation
99 years or below
All
Phase
2
10 participants needed
1 Location
Brief description of study
To evaluate progression-free survival (PFS) using traditional RECIST critiera with the combination of fulvestrant and palbociclib vs. fulvestrant alone in patients with advanced HR+/HER2- breast cancer that has progressed despite prior CDK4/6 inhibition and endocrine therapy.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: breast cancer
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 831197
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
